source
- Merck launches voluntary licensing for investigational monthly HIV PrEP pill ahead of approvalMerck has signed voluntary licensing agreements to allow generic manufacturers to produce its investigational monthly HIV PrEP pill, alimatravir, before any regulatory submission. The agreements c…
- Sanofi drops pursuit of eczema drug amlitelimab after failed Phase 3 trialsSanofi announced it will no longer seek regulatory approval for amlitelimab, an anti‑OX40 ligand antibody intended for atopic dermatitis, after recent Phase 3 data fell short of expectations. The…